Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It is indicated for the treatment of diabetic macular edema in adult patients, providing long‑term anti‑inflammatory and anti‑vascular permeability effects within the retina.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide under EU‑approved standards. The company supports regulatory documentation, cold‑chain logistics and post‑market surveillance for its ophthalmic implant portfolio globally.

Iluvien (fluocinolone acetonide) is used to manage ocular conditions characterized by retinal edema and vascular leakage.

Diabetic macular edema: reduces retinal swelling and can improve visual acuity.

Iluvien may cause ocular adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Increased intraocular pressure - Cataract formation or progression - Ocular pain or discomfort - Decreased visual acuity

Serious or Rare Side Effects: - Retinal detachment - Endophthalmitis (intraocular infection) - Vitreous hemorrhage - Severe optic nerve damage

Prior to implantation, clinicians should evaluate patients for factors that may increase the risk of complications. - Monitor intraocular pressure: schedule regular IOP assessments after implantation. - Assess cataract status: consider baseline lens opacity and potential progression. - Avoid in active ocular infection: postpone implantation until infection resolves. - Use caution in glaucoma patients: evaluate risk of steroid‑induced pressure rise. - Review systemic corticosteroid exposure: limit concurrent systemic steroids when possible. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iluvien can interact with other medications that affect corticosteroid activity or ocular physiology.

Major Interactions (Avoid): - Systemic corticosteroids: additive glucocorticoid effects may increase systemic exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise intraocular drug levels. - Antifungal azoles: potential increase in fluocinolone concentration.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Anti‑VEGF agents: coordinate timing to avoid overlapping procedures.